Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

F) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1a, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulat
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) ... to Prepare Application Dossiers for Oversea Medical device ... report to their offering. The ... market of the most growth potentiality, which is ... and producers to penetrate such market. It is ...
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... Partners, Aesculap and Tornier, Conduct Clinical ... Evaluations of TephaFLEX(R) Suture Products, LEXINGTON, Mass., ... derived from a new class of polymers, announced today ... conducting initial,clinical evaluations of the Company,s new TephaFLEX(R) suture ...
... (Nasdaq: KOSN ) presented preclinical data on ... vitro and in vivo,activity as well as tolerability ... anticancer mechanism of action correlating inhibition,of the target ... cells,compared to normal cells. Data on Kosan,s NEIs ...
Cached Medicine Technology:Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:5/25/2015)... 25, 2015 Decora Preset 60 Minute ... now available on ‘The Hardware City.’ The product helps in ... set a time and the related electronic device is automatically ... representative of the company said, “We are glad that this ... customers can buy Countdown Timer Switch in just a few ...
(Date:5/24/2015)... May 24, 2015 For people who ... Chinese Enterokinase Industry, 2009-2019 Market Research Report would be ... an exhaustive study on the present market scenario of ... into the growing Chinese market of this industry. The ... overall status of the manufacturers in this industry. The ...
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... Beach, CA (PRWEB) May 23, 2015 Dr. ... Beach, California, has just posted a new article ... gauge repair. As Dr Benvenuti explained in the ... wear enlarged plugs in their earlobes. , Known as “gauging,” ... the earlobe hole, which Dr. Benvenuti said will eventually stretch ...
Breaking Medicine News(10 mins):Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2
... a 25 year old British man, Andrew Stimpson who claims his body ... Trust, warns that too many people have been 'jumping to // conclusions' ... told two newspapers he had tested positive for HIV in August 2002, ... ...
... While scientists world over have hailed the results of ... GlaxoSmithKline (GSK), that has halved the incidence of severe ... warned that malaria vaccination is still a far off ... of a medical breakthrough, Pierre Druilhi, director of the ...
... the national nursing shortage by producing more qualified nursing ... Robert W. Woodruff Foundation has awarded // $995,000 to ... support its new doctorate of nursing practice program, the ... ,Thanking the Atlanta-based Woodruff Foundation, a private organization, for ...
... BEIJING: China finally admitted on Friday that bird flu ... to control the disease, while leaders at an Asia-Pacific ... // more human infections., ,President Bush, Chinese President ... President Vladimir Putin were among the leaders pledging unity ...
... and chief ministers of India's northeastern states are expected ... a political commitment to combat the disease that has ... ,A daylong conclave on tackling the scourge is being ... the parliamentary committee on HIV/AIDS. UNAIDS Executive Director Peter ...
... high-risk medication by the FDA, doctors have been found to ... patients found to receive // such drugs was nearly ... and Harvard Pilgrim Health Care. ,The response of the ... variable, with noncompliance rates soaring from 0.3 % to 49.6%. ...
Cached Medicine News:Health News:‘Miracle’ HIV Cure Claim Under Scrutin 2Health News:Controversy: Malaria Vaccine - Future Possibility Or Just A Dream? 2Health News:Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program 2Health News:Bird Flu Spreading in China's Poultry 2Health News:North-Eastern Leaders Of India Meet To Discuss HIV Problems 2Health News:Doctors Do Not Excise Sufficient Caution While Prescribing High-Risk Drugs 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: